JPS5965013A - 上部尿路平滑筋拡張剤 - Google Patents
上部尿路平滑筋拡張剤Info
- Publication number
- JPS5965013A JPS5965013A JP58149281A JP14928183A JPS5965013A JP S5965013 A JPS5965013 A JP S5965013A JP 58149281 A JP58149281 A JP 58149281A JP 14928183 A JP14928183 A JP 14928183A JP S5965013 A JPS5965013 A JP S5965013A
- Authority
- JP
- Japan
- Prior art keywords
- ester
- group
- administered
- body weight
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 26
- 210000001635 urinary tract Anatomy 0.000 title claims description 23
- 210000003205 muscle Anatomy 0.000 title 1
- 230000037396 body weight Effects 0.000 claims description 19
- -1 aminoether ester Chemical class 0.000 claims description 17
- DGNVBABJWSEPJZ-UHFFFAOYSA-N 2,2-diphenylethanethioic s-acid Chemical compound C=1C=CC=CC=1C(C(=O)S)C1=CC=CC=C1 DGNVBABJWSEPJZ-UHFFFAOYSA-N 0.000 claims description 16
- 210000002460 smooth muscle Anatomy 0.000 claims description 15
- 125000003277 amino group Chemical class 0.000 claims description 13
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 9
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
- 208000000913 Kidney Calculi Diseases 0.000 claims description 8
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 8
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 4
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical class NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 claims description 3
- 230000000916 dilatatory effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 241000907681 Morpho Species 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 11
- 230000008602 contraction Effects 0.000 description 10
- 241000282887 Suidae Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 230000010339 dilation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010051958 Ureteral spasm Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000369 acute toxicity data Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- MZWKCFGWAWRHDY-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] 2,2-diphenylethanethioate;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 MZWKCFGWAWRHDY-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/412,238 US4432977A (en) | 1982-08-27 | 1982-08-27 | Method for dilating the smooth muscles of the upper urinary tract |
| US412238 | 1989-09-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5965013A true JPS5965013A (ja) | 1984-04-13 |
| JPS6350329B2 JPS6350329B2 (enExample) | 1988-10-07 |
Family
ID=23632192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58149281A Granted JPS5965013A (ja) | 1982-08-27 | 1983-08-17 | 上部尿路平滑筋拡張剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4432977A (enExample) |
| EP (1) | EP0102554B1 (enExample) |
| JP (1) | JPS5965013A (enExample) |
| AU (1) | AU554173B2 (enExample) |
| DE (1) | DE3371168D1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707480A (en) * | 1983-04-14 | 1987-11-17 | United Pharmaceuticals, Inc. | Method for stabilizing a detrusor muscle while increasing detrusor muscle strength |
| US4714707A (en) * | 1984-01-13 | 1987-12-22 | Rorer Pharmaceutical Corporation | Aryl substituted heterocycles for treating gastrointestinal motility dysfunction |
| US4766119A (en) * | 1985-02-20 | 1988-08-23 | United Pharmaceuticals, Inc. | Antispasmodic alkylated aminothioester derivatives |
| US4725593A (en) * | 1985-02-20 | 1988-02-16 | United Pharmaceuticals, Inc. | Method of treating smooth muscle spasm |
| US4721722A (en) * | 1985-07-12 | 1988-01-26 | United Pharmaceuticals, Inc. | Anti-spasmodic agents containing quaternary nitrogen |
| US4721783A (en) * | 1986-01-09 | 1988-01-26 | United Pharmaceuticals, Inc. | Anti-spasmodic agents having a heterocyclic ring |
| USRE33907E (en) * | 1986-01-09 | 1992-04-28 | United Pharmaceuticals, Inc. | Anti-spasmodic agents having a heterocyclic ring |
| US4857535A (en) * | 1986-01-09 | 1989-08-15 | United Pharmaceuticals | Anti-spasmodic agents having a heterocyclic ring |
| DE3742580C1 (de) * | 1987-12-16 | 1989-05-11 | Schaper & Bruemmer Gmbh | Verwendung des alpha,alpha-Diphenyl-alpha-(3-carboxy-propionyloxy)-essigsaeure-4-(N-methylpiperidyl)-esters zur Behandlung hypertoner Funktionszustaende im Bereich der Harnblase |
| US5146193A (en) * | 1991-02-25 | 1992-09-08 | Motorola, Inc. | Monolithic ceramic filter or duplexer having surface mount corrections and transmission zeroes |
| US5147667A (en) * | 1991-03-26 | 1992-09-15 | Nestec S.A. | Beef flavor |
| US5130336A (en) * | 1991-11-15 | 1992-07-14 | United Pharmaceuticals, Inc. | Method for treatment for neuro-muscular incontinence |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390555A (en) * | 1943-08-03 | 1945-12-11 | Poythress William P & Co | Antispasmodic agents |
-
1982
- 1982-08-27 US US06/412,238 patent/US4432977A/en not_active Expired - Lifetime
-
1983
- 1983-08-08 AU AU17671/83A patent/AU554173B2/en not_active Ceased
- 1983-08-10 DE DE8383107891T patent/DE3371168D1/de not_active Expired
- 1983-08-10 EP EP83107891A patent/EP0102554B1/en not_active Expired
- 1983-08-17 JP JP58149281A patent/JPS5965013A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| EP0102554B1 (en) | 1987-04-29 |
| US4432977A (en) | 1984-02-21 |
| AU554173B2 (en) | 1986-08-07 |
| DE3371168D1 (en) | 1987-06-04 |
| JPS6350329B2 (enExample) | 1988-10-07 |
| AU1767183A (en) | 1984-03-01 |
| EP0102554A1 (en) | 1984-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Madersbacher et al. | Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride | |
| RU2152786C2 (ru) | Средство для лечения недержания мочи | |
| JP2020510016A5 (enExample) | ||
| JPS61277620A (ja) | 排尿困難治療剤 | |
| JPS5965013A (ja) | 上部尿路平滑筋拡張剤 | |
| JP2002532392A5 (enExample) | ||
| KR20060134041A (ko) | 음식물 섭취 관리 방법 | |
| Barrowman et al. | Diarrhoeae in thyroid medullary carcinoma: role of prostaglandins and therapeutic effect of nutmeg. | |
| JP2000511873A (ja) | 睡眠時呼吸障害を治療および診断する方法、並びにこの方法を実施する手段 | |
| KR20040030788A (ko) | 요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체 | |
| BG62120B1 (bg) | Фармацевтични състави за ректално приложение наалкилсулфонамиди - агонисти на 5-нт1 | |
| Santo et al. | Bilateral cingulumotomy in the treatment of reflex sympathetic dystrophy | |
| JPH0196131A (ja) | 睡眠障害および鬱病を治療するためのある種の化合物の使用 | |
| CN114948980A (zh) | 一种预防和/或治疗焦虑性失眠的药物组合物及其应用 | |
| JP4370054B2 (ja) | 腸粘膜傷害の予防及び治療剤 | |
| US20020091161A1 (en) | Novel long acting, reversible veterinary sedative & analgesic and method of use | |
| EA199800781A1 (ru) | Применение 2-(3,4-диметоксициннамоил) аминобензойной кислоты для изготовления лекарственного средства для лечения или предотвращения рестеноза | |
| WO2002022127A1 (en) | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders | |
| Vaidyanathan et al. | Intravenous salbutamol treatment for penile erection arising during cystoscopy of cervical spinal cord injury patients | |
| JP2020045332A (ja) | 慢性便秘症を治療するための医薬組成物 | |
| Woodward | Current management of neurogenic bladder in patients with MS | |
| Hart | Flurbiprofen in the treatment of ankylosing spondylitis | |
| CN116059206A (zh) | 2-氨基喹啉在治疗腹泻药物中的应用 | |
| RU2065303C1 (ru) | Способ лечения онкологических больных | |
| Kantor | THE INTRA-INTESTINAL TUBE TREATMENT OF HOOKWORM INFECTION |